drugset / Trial / NCT00630500
Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
Phase 2
Completed
75 enrolled
Helse Stavanger HF
King's College London · collabLund University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A 24-week placebo-controlled parallel group multicentre trial to study the safety and efficacy of memantine in patients with dementia associated with Parkinson's disease and dementia with Lewy bodies. It is hypothesized that memantine will be safe and well tolerated, and more effective than placebo.
Timeline
- Start
- 2006-02
- Primary completion
- 2009-02
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Memantine | Unknown | 5 mg | — |
| Comparator | Memantine | Unknown | 10 mg | — |